Drug Positioning Statements

Drug Positioning Statements (DPSs) provide prescribers with recommendations for specific primary / secondary care interface drugs. Prescribers should look for the verdict section, at the bottom of the document in older versions, which describes the APC's recommendation should a rapid appraisal of a drug's positioning locally be required.The DPS document also appraises the evidence and has a drug summary.

These are key documents and prescribers should familiarise themselves with this section of the website and look for new additions regularly

 

TO SEARCH FOR A DOCUMENT, PLEASE USE THE SHOW SEARCH  BUTTON FIELD BELOW.

 NameDescriptionLast Modified  
DPS006 - Liraglutide [Type 2 Diabetes treatment].pdf Version: 2.4 21 Mar 2019 18:26:50
DPS008 - Roflumilast.pdf Version: 3.0 01 May 2019 11:41:53
DPS010 - Capsaicin patch (Qutenza) [Peripheral neuropathic pain].pdf Version: 3.1.1 14 Jul 2017 10:09:41
DPS014 - Prucalopride [Constipation in men and women].pdf Version: 3.1.1 14 Jul 2017 10:09:41
DPS018 - Tapentadol SR Version: 6.0 10 May 2019 17:38:11
DPS019 - Low Molecular Weight Heparins (LMWHs) - Unlicensed.pdf Version:2.0 14 Jun 2019 10:00:21
DPS022 - Asenapine.pdf Version: 2.1.1 14 Jul 2017 10:09:41
DPS023 - Dabigatran [Stroke prevention in AF].pdf Version: 4.0 30 Aug 2018 14:51:47
DPS030 - Rivaroxaban [Stroke Prevention in AF].pdf Version: 4.0 30 Aug 2018 14:50:15
DPS031 - Rivaroxaban [[Treatment and secondary prevention of DVT and PE].pdf Version: 4.1 21 Jan 2019 15:08:47
123456

Share